2012
DOI: 10.1016/j.tracli.2012.02.003
|View full text |Cite
|
Sign up to set email alerts
|

CD40 ligand (CD154) involvement in platelet transfusion reactions

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
39
0
2

Year Published

2013
2013
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 43 publications
(45 citation statements)
references
References 35 publications
4
39
0
2
Order By: Relevance
“…The secretion profile of many of these BRMs appears to depend solely on the shelf-life of the platelets, [2], [15], [20],[21],[31],[32], but it may be modified by the initial (whole blood buffy-coat pools vs. SDA-PCs) or additional processes (PAS vs. 100% autologous plasma) [33]. The profile also depends on the type of cell separator when considering SDA-PCs [33].…”
Section: Resultsmentioning
confidence: 99%
“…The secretion profile of many of these BRMs appears to depend solely on the shelf-life of the platelets, [2], [15], [20],[21],[31],[32], but it may be modified by the initial (whole blood buffy-coat pools vs. SDA-PCs) or additional processes (PAS vs. 100% autologous plasma) [33]. The profile also depends on the type of cell separator when considering SDA-PCs [33].…”
Section: Resultsmentioning
confidence: 99%
“…These problems reduce the efficacy of platelet transfusion therapy. Stored platelets also express significant levels of CD40L which was shown to trigger pro-inflammatory pathways via the interaction with different types of leukocytes [11,12].…”
Section: Discussionmentioning
confidence: 99%
“…L'usage de PSL frais (CGR, CP) n'est pas appliquée en routine mais peut être négociée sur accords professionnels dans des circonstances particulières (en plus de la néonatalogie et de la pédiatrie où elle est appliquée en semi-routine) [84]. Certaines équipes proposent, -pour certains patients -soit des lavages de CGR ou de CP pour les déplasmatiser et ôter, soit ses IgA en cas d'Ac anti-IgA avérés ou supposés, soit des BRM pro-inflammatoires (une alternative étant l'absorption sur colonne), bien que -comme déjà indiqué -cette manifestation IgA anti-IgA soit à reconsidérer [67,74,[85][86][87][88][89].…”
Section: Actions Entreprises Au Niveau Des Produits (Psl)unclassified